Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation

Front Immunol. 2023 Mar 28:14:1148111. doi: 10.3389/fimmu.2023.1148111. eCollection 2023.

Abstract

In hepatitis B virus (HBV) infection, the interplay between the virus and the host immune system is crucial in determining the pathogenesis of the disease. Patients who fail to mount a sufficient and sustained anti-viral immune response develop chronic hepatitis B (CHB). T cells and natural killer (NK) cells play decisive role in viral clearance, but they are defective in chronic HBV infection. The activation of immune cells is tightly controlled by a combination of activating and inhibitory receptors, called immune checkpoints (ICs), allowing the maintenance of immune homeostasis. Chronic exposure to viral antigens and the subsequent dysregulation of ICs actively contribute to the exhaustion of effector cells and viral persistence. The present review aims to summarize the function of various ICs and their expression in T lymphocytes and NK cells in the course of HBV infection as well as the use of immunotherapeutic strategies targeting ICs in chronic HBV infection.

Keywords: HBV; NK cells; T cells; anti-viral activity; immune checkpoint molecules.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Hepatitis B virus
  • Hepatitis B*
  • Hepatitis B, Chronic*
  • Humans
  • Killer Cells, Natural

Substances

  • Antiviral Agents

Grants and funding

This work has received supports from the European Union’s Horizon 2020 research and innovation program (IP-Cure-B project, grant agreement No 847939) and from “Ligue contre le Cancer AuRA”.